Results 21 to 30 of about 6,174 (184)

Darovasertib, a novel treatment for metastatic uveal melanoma

Frontiers in Pharmacology, 2023
The FDA granted orphan drug designation to darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C (PKC), for the treatment of uveal melanoma, on 2 May 2022.
Lei Cao, Shuzhen Chen, Rainie Sun, Rainie Sun, Charles R. Ashby, Liuya Wei, Zoufang Huang, Zhe-Sheng Chen   +7 more
doaj   +1 more source

Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. [PDF]

, 2016
BackgroundNovel therapies are needed for children with high-risk and relapsed neuroblastoma. We hypothesized that MAPK/ERK kinase (MEK) inhibition with the novel MEK1/2 inhibitor binimetinib would be effective in neuroblastoma preclinical models ...
Liu, Yin, Scorsone, Kathleen A, Woodfield, Sarah E, Zage, Peter E, Zhang, Linna   +4 more
core   +2 more sources

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

Gynecologic Oncology Reports, 2018
Background: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC.CASE: A 65-year-old woman with recurrent widespread ...
Chanhee Han, Stefania Bellone, Luca Zammataro, Peter E. Schwartz, Alessandro D. Santin   +4 more
doaj   +1 more source

A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

Molecules, 2022
The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi™, ENF) plus binimetinib (Mektovi®, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600 ...
Mohamed M. Hefnawy, Mohammed M. Alanazi, Abdullah M. Al-Hossaini, Abdulaziz I. Alnasser, Adel S. El-Azab, Yousef A. Bin Jardan, Mohamed W. Attwa, Manal A. El-Gendy   +7 more
doaj   +1 more source

Emerging treatment options for BRAF-mutant colorectal cancer. [PDF]

, 2018
The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments.
Atreya, Chloe E, Ursem, Carling, Van Loon, Katherine   +2 more
core   +2 more sources

In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms [PDF]

, 2018
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo
Aplin, Andrew E., Cheng, Phil F., Chervoneva, Inna, Davies, Michael A., Dummer, Reinhard, Ertel, Adam, Fortina, Paolo, Hookim, Kim, Kleiber, Ines, Kwong, Lawrence N., Levesque, Mitch P., Nikbakht, Neda, Patel, Prem, Purwin, Timothy J., Teh, Jessica L. F.   +14 more
core   +1 more source

Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance

Journal of Cutaneous Immunology and Allergy, 2023
While combined use of BRAF/MEK inhibitors has elicited dramatic clinical efficacy in incurable melanoma, drug‐associated retinopathy has become an emerging adverse event.
Takumi Hasegawa, Shiro Iino, Misako Fujisaki, Sayuri Okamura, Natsuki Baba, Nami Tanaka, Yuko Takeuchi, Noritaka Oyama, Minoru Hasegawa   +8 more
doaj   +1 more source

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design [PDF]

, 2022
BRAF V600 mutation; Binimetinib; EncorafenibMutació de BRAF V600; Binimetinib; EncorafenibMutación de BRAF V600; Binimetinib; EncorafenibBRAFV600 oncogenic driver mutations occur in 1–2% of non-small-cell lung cancers (NSCLCs) and have been shown to be a
Ahn, Myung-Ju, Felip Font, Enriqueta, Ramalingam, Suresh, Riely, Gregory, Smit, Egbert, Tsao, Anne   +5 more
core   +1 more source

Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab

Case Reports in Oncology, 2020
Activating RAS mutations occur in more than a half of colorectal cancers (CRCs). RAS-mutated CRCs are notoriously difficult to treat given that they are characterized by the aggressive disease course and the lack of appropriate targeted therapies. Recent
Sergey V. Orlov, Magaripa A. Urtenova, Maria A. Sviridenko, Denis V. Nesterov, Tatiana N. Sokolova, Evgeny N. Imyanitov   +5 more
doaj   +1 more source

Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. [PDF]

, 2019
Whole exome sequencing (WES), targeted gene panel sequencing and single nucleotide polymorphism (SNP) arrays are increasingly used for the identification of actionable alterations that are critical to cancer care.
Carpten, John D, Kaur, Pushpinder, Lang, Julie E, Porras, Tania B, Ring, Alexander   +4 more
core   +3 more sources